Alvotech secures $75 million additional term loan facility from GoldenTree

Alvotech announced on July 1, 2026 that it had amended its existing credit agreement with funds managed by GoldenTree Asset Management LP and other existing lenders to provide a term loan facility of up to $75 million in additional capital.¹

The new facility follows the $165 million equity capital raise announced on June 18, 2026, and supports continued execution of the company's growth strategy, including advancing its biosimilar pipeline, product launches and expanding global commercial operations.¹ Combined with the equity raise, including the equity financing and the undrawn term loan facility the company has secured access to $240 million in new capital.¹

The facility expands the company's existing credit agreement by providing an additional $75 million term loan facility alongside the $100 million term loan facility announced in December 2025, and it bears an interest rate of 12.50%, payable monthly in cash, with a maturity date of December 31, 2027.¹ The arrangement builds on Alvotech's existing relationship with GoldenTree, which has been a long-term financing partner to the company.¹

Founder and chairman Robert Wessman said the financing provides flexibility for the company's strategic priorities, and cited recent milestones including the resubmission of key Biologics License Applications to the FDA, continued advancement of its pipeline including FDA acceptance of its BLA for a biosimilar to Entyvio, and expansion of its global commercial footprint.¹

Alvotech describes itself as having five biosimilars already approved and marketed in multiple global markets, including biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, with a current development pipeline that includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.¹